

The 14th International Symposium on Myelodysplastic Syndromes

Plenary Session	Interactive Session	Parallel Session	Meet the Expert	Patients Forum	Nurses Program
Social Event	Oral Session	Tito Bastianello and MDS Foundation Young Investigators Award	Industry Sessions	Guided Poster Session	Pharmacist Session

Wednesday, May 3, 2017

Time	Auditorium 1	Auditorium 2	Auditorium 3	Exhibition Area
12:00 - 14:00		 <p>Workshop I: Flow Cytometry</p> <p>Chair: Alberto Orfao, Spain</p> <p>Welcome and Introduction Alberto Orfao, Spain</p> <p>ELN Recommendations on Flow Immuno-Phenotyping in MDS Arjan A. van de Loosdrecht, The Netherlands</p> <p>Normal vs MDS-Associated Phenotypes of CD34+ Precursors Alberto Orfao, Spain</p> <p>Altered Phenotypes of Maturing Neutrophils in MDS Amparo Sempere Spain</p> <p>Altered Monocytic Maturation in MDS Sergio Matarraz, Spain</p> <p>Multicentric Detection of Dysplastic Erythroblast Phenotypes In MDS: Is There a Need for Standardization? Theresia M. Westers, The Netherlands</p> <p>Case Presentation Alberto Orfao, Spain</p> <p>Final Remarks and Conclusion</p>		

14:00 - 16:00

Workshop II: From Chromosome Banding to NGS - A Diagnostic Approach to MDS



Chair:
Francesc Solé, Spain

Welcome
Francesc Solé, Spain

Interactive Questions
José Cervera, Spain

The Best and Worst of: Cytogenetics
Detlef Haase, Germany

The Best and Worst of: FISH
Cristina Mecucci, Italy

The Best and Worst of: SNP/CGH Arrays
José Cervera, Spain

The Best and Worst of: NGS
Rafael Bejar, USA

Selected Cases

Closing Remarks
Francesc Solé, Spain

16:00 - 18:00



**Workshop III:
Cytomorphology**

Chair:
Teresa Vallespí, Spain

Welcome
Teresa Vallespí

Introduction
Jean Goasguen, France

Workshop objectives:

- Definition of DysE, DysG, DysMeg and Blast Cut-Off
- Definition of Blast Cell and Method to Count
- Current Classification

Dyserythropoiesis
Teresa Vallespí, Spain

Dysgranulopoiesis
Jean Goasguen, France

Dysmegakaryocytopoiesis
Ulrich Germing, Germany

Blast Cells and How to Count
Jean Goasguen, Spain

Introduction to a Clinical Case
Ulrich Germing, Germany

Clinical case: Extreme Granulocytic Dysplasia in
a de Novo Myelodysplastic Syndrome
Eduardo Rodríguez, Spain

Final remarks

Opening Ceremony

Chair: **Stephen D. Nimer**, USA
Guillermo F. Sanz, Spain

Introductory Welcome
Guillermo F. Sanz, Spain

Welcome from the MDS Foundation
Stephen D. Nimer, USA

Clonal Diversity and Clonal Evolution in MDS Progression
Timothy Graubert, USA

Tito Bastianello Young Investigator Awards Announcement
Stephen D. Nimer, USA

Concert
Orquesta Filarmónica Martín i Soler de Valencia and
Orquesta Unión Musical Santa Cecilia de Onda.
Conductor:
Carmen Más Arocas

18:30 - 20:00



20:00

Welcome Reception

Ticket

Pre-registration and payment required to attend

Thursday May 4, 2017

Time	Sala 1+2	Sala 8+9	
07:30-08:00	 <p style="text-align: center;">Meet the Expert</p> <p style="text-align: center;">Geriatric Evaluation Reinhard Stauder, Austria</p>	 <p style="text-align: center;">Meet the Expert</p> <p style="text-align: center;">Mesenchymal Cells in MDS Consuelo del Cañizo, Spain</p>	
	Auditorium 1	Auditorium 2	Auditorium 3
08:00 – 09:30	<p>MDS Biology and Pathogenesis 1</p> <p>Chairs: Rafael Bejar, USA Juan Cruz Cigudosa, Spain</p> <p>MDS: A Stem Cell Disorder Stephen D. Nimer, USA</p> <p>Driver and Late Occurring Somatic Mutations Elli Papaemmanuil, USA</p> <p>Epigenetic Deregulation Maria E. Figueroa, USA</p> <p><i>Oral Abstract Presentation:</i> Ancestral Events Including Germline and Somatic Mutations Determine Subclonal Events and Affect Phenotype of Progression in MDS Yasunobu Nagata, USA</p> <p><i>Oral Abstract Presentation:</i> Therapeutic Targeting of MDS AML Stem Cells with An Antisense Inhibitor of STAT3 Aditi Shastri, USA</p>		
09:30-10:00	Coffee Break, Exhibition & Poster Viewing		

MDS Biology and Pathogenesis 2

Chairs:

Benjamin L. Ebert, USA

Stephen D. Nimer, USA

Aging, CHIP, and MDS

David P. Steensma, USA

The Aberrant Spliceosome Machinery

Seishi Ogawa, Japan

Deregulation of the Innate Immune System

Alan F. List, USA

Oral Abstract Presentation:

Identification of Aberrant Splicing Events in Myelodysplastic Syndrome Patients with Splicing Factor Gene Mutations

Andrea Pellagatti, UK

Oral Abstract Presentation:

RNA sequencing reveals TGF Beta Mediated Functional Inhibition of Mesenchymal Stromal Cells in MDS

Thomas Schroeder, Germany

10:00-11:30

<p>11:30-13:00</p>	<p>Diagnosis and Prognosis of MDS / New Challenges and New Approaches</p> <p>Chairs: Patricia Font, Spain Guillermo Sanz, Spain</p> <p>2016 WHO classification: Main Changes Ulrich Germing, Germany</p> <p>Cytogenetics: Still Alive? Francesc Solé, Spain</p> <p>Somatic Mutations: A Role for Improving Diagnosis and Risk Assessment? Rafael Bejar, USA</p> <p><i>Oral Abstract Presentation:</i> Prognostic Significance of Serial Molecular Annotation in Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML) David Sallman, USA</p>		
---------------------------	--	--	--



	<p><i>Oral Abstract Presentation:</i> Prognostic Value of Early Drop in Platelets in Lower-risk MDS. A Sub-Study from the European LeukemiaNet Lower-Risk MDS (EUMDS) Registry Raphael Itzykson, France</p>		
--	--	--	--

<p>13:00 - 15:00</p>	<p>Lunch Break, Exhibition & Poster Viewing</p>		
	<p>13:15-14:45 Industry Supported Session not included in the CME/CPD Program</p>		

<p>15:00 - 16:30</p>	<p style="text-align: center;">Oral Session 1</p> <p style="text-align: center;">Chairs: Eric Padron, USA Maria E. Diez Campelo, Spain</p> <p>Characterization of novel oral splicing modulator, H3B-8800, identifies the mechanistic basis for its preferential lethality towards spliceosome-mutant myeloid malignancy models Silvia Buonamici, USA</p> <p>Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, myelodysplastic syndrome and neurological symptoms Bianca Tesi, Sweden</p> <p>Health-related quality of life is substantially impaired in lower-risk MDS when compared with reference populations and significantly affects overall survival Reinhard Stauder, Austria</p> <p>Romiplostim In Low/Int-1-Risk MDS Results in Reduced Bleeding Without Impacting Leukemic Progression: Final Results from A Randomized, Double-Blind, Placebo-Controlled Study</p>	<p style="text-align: center;">Oral Session 2</p> <p style="text-align: center;">Chairs: Benjamin Ebert, USA Jose Cervera, Spain</p> <p>Spanish Guidelines for the use of targeted deep sequencing in MDS and CMML Laura Palomo, Spain</p> <p>The S100A9-FTO Axis Directs Genetic Instability in Myelodysplastic Syndromes (MDS) Erika Eksioglu, USA</p> <p>Novel role of S100A9-induced overexpression of PD-1/PD-L1 in HSPC and MDSC contribute to ineffective hematopoiesis in MDS Sheng Wei, USA</p> <p>Persistence of preleukemic clonal hematopoiesis after chemotherapy is associated with poor prognosis in patients with high risk MDS and AML Koichi Takahashi, USA</p> <p>Dual deficiency of mDia1 and miR-146a in an age-related inflammatory</p>	<p style="text-align: center;">Nurse Session A</p> <p style="text-align: center;">Chairs: Inmaculada Vaquero, Spain Petra Lindroos Köllqvist, Sweden</p> <p>Health, Technology and Educational Preferences in MDS Patients: Results of An Online Survey Sandra Kurtin, USA</p> <p>Home Care for MDS Patients Undergoing Allogeneic Hematopoietic Cell Transplantation Nuria Borrás, Spain</p> <p>Azacitidine Administration at Home Laura Muñoz, Spain</p>
	<p>16:30-17:00</p>	<p style="text-align: center;">Pierre Fenaux, France</p> <p>Impact of Gene Mutations on Response to Lenalidomide and OS In Lower-Risk Non-Del(5q) MDS Patients Ineligible/Refractory to Erythropoiesis-Stimulating Agents (ESAs) Valeria Santini, Italy</p> <p>CC-486 (Oral Azacitidine) Induces Responses in Patients with Hematological Malignancies Who Had Failed Prior Treatment with Injectable Hypomethylating Agents (HMAs) Guillermo Garcia-Manero, USA</p>	<p>bone marrow microenvironment induces ineffective erythropoiesis that phenocopies del(5q) MDS Peng Ji, USA</p> <p>Distinct genetic alterations in <i>DHX9</i> and its clinical significance and biological function in the patients with myelodysplastic syndromes Xiao Li, China</p>
<p>Coffee Break, Exhibition & Poster Viewing</p>			

<p>17:00-18:30</p>	<p align="center">Biology and Management of CMML</p> <p align="center">Chairs: Eric Padron, USA Blanca Xicoy, Spain</p> <p>Relevance of Flow Cytometry, Cytogenetics, Somatic Mutations, and Epigenetic Alterations in CMML Eric Solary, France</p> <p>Risk Assessment in CMML Luca Malcovati, Italy</p> <p>Current Management and Investigational Approaches Eric Padron, USA</p> <p><i>Oral Abstract Presentation:</i> Hypomethylating Agent Therapy Use and Survival in Older Patients with Chronic myelomonocytic Leukemia in USA: A Large Population-Based Study Amer Zeidan, USA</p> <p><i>Oral Abstract Presentation:</i> MDS With Isolated Trisomy 8: A Type of MDS Frequently Associated With Myeloproliferative Features? A Report by the GFM Louis Drevon, France</p>		<p align="center">Nurse Session B 17:00-19:30</p> <p align="center">Chairs: Nuria Borrás, Spain Sandra Kurtin, USA</p> <p>Transfusional Support Assessment in MDS Inmaculada Vaquero, Spain</p> <p>Current Treatment of MDS Joaquín Sánchez-García, Spain</p> <p>MDS in Childhood: Special Considerations Eugenia Trigo, Spain</p> <p>PhotoVoice for MDS patients Petra Lindroos Kölqvist, Sweden</p>
<p>18:30-19:30</p>	<p align="center">Predicting Response to Therapy</p> <p align="center">Chair: Raphael Itzykson, France Valeria Santini, Italy</p> <p>Prediction of ESAs and Lenalidomide Benefit Maria E. Díez Campelo, Spain</p> <p>Prediction of Azacitidine Benefit Raphael Itzykson, France</p> <p>Predicting Transplantation Outcomes Matteo G. Della Porta, Italy</p>	<p align="center">Health Economics and Outcome Research</p> <p align="center">Chair: David Bowen, UK Mikkael Sekeres, USA</p> <p>Regulatory Aspects and Cost Effectiveness Analysis of Drugs in Europe David Bowen, UK</p> <p>Cost of Care of MDS Patients in USA Trever Burgon, USA</p> <p>Patient Reported Outcomes in MDS Fabio Efficace, Italy</p>	
<p>19:30-20:30</p>			<p align="center">Industry Supported Session not included in the CME/CPD Program</p>

Friday May 5, 2017

Friday May 5, 2017				
Time	Sala 1+2	Sala 8+9		
08:00-08:30	 <p>Meet the Expert The Future of Genomics in MDS: What Will We Require for Our Clinical Daily Practice? Jaroslav Maciejewski, USA</p>	 <p>Meet the Expert Treatment After Failure of Hypomethylating Agents? Lionel Ades, France</p>		
Time	Auditorium 1	Auditorium 2	Auditorium 3	Patient Forum at Auditorium Hospital Universitari i Politécnic La Fe

<p>08:30 - 10:00</p>	<p style="text-align: center;">Singular Subtypes of MDS</p> <p style="text-align: center;">Chairs: Aristoteles Giagounidis, Germany Joaquín Sánchez-García, Spain</p> <p style="text-align: center;">Insights into the mechanism of action of lenalidomide in patients with deletion 5q Benjamin L. Ebert, USA</p> <p style="text-align: center;">Clonal evolution in aplastic anemia and hypoplastic MDS Ghulam J. Mufti, UK</p> <p style="text-align: center;">New developments in childhood MDS Charlotte M. Niemeyer, Germany</p> <p style="text-align: center;"><i>Oral Abstract Presentation:</i> Genome-Wide DNA Methylation Profiling Reveals Distinct Molecular Subgroups of Juvenile Myelomonocytic Leukemia with Clinical Significance</p>			
	<p style="text-align: center;">Christian Flotho, Germany</p> <p style="text-align: center;"><i>Oral Abstract Presentation:</i> <i>TET2</i> Is Iron-Dependent So Its Activity May Be Compromised in <i>SF3B1</i> Mutated Age-Related Clonal Hematopoiesis of Indeterminate Potential Tomas Radivoyevitch, USA</p>			
<p>10:00 - 10:30</p>	<p>Coffee Break, Exhibition & Poster Viewing</p>			

Therapy-1 Current Options

Chairs:

Teresa Bernal, Spain
Uwe Platzbecker, Germany

How I treat MDS patients?
Pierre Fenaux, France

Management of MDS with 5q- after lenalidomide failure
Aristoteles Giagounidis, Germany

Looking for the best partner for hypomethylating agents in
higher-risk patients
Mikael Sekeres, USA

Oral Abstract Presentation:

Challenging IWG2006 Response Criteria: Results of A
Randomized Study of Epoetin Alfa Versus Placebo in Anemic
Lower Risk MDS Patients
Pierre Fenaux, France

10:30 - 12:00

Oral Abstract Presentation:

Eltrombopag In Combination with Azacitidine For First-Line
Treatment of MDS Patients with Thrombocytopenia: The
Randomized, Placebo-Controlled, Phase III, Support Study
Michael Dickinson, Australia

Therapy-2 New Developments

Chairs:

Maria E. Diez Campelo, Spain
Alan F. List, USA

Clinical trials in Europe
Lionel Ades, France

Clinical trials in USA
Guillermo García-Manero, USA

12:00 - 13:30

New agents for anemic patients: modified activin receptors
Uwe Platzbecker, Germany

Oral Abstract Presentation:

Enasidenib (Ag-221), A Selective Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, In Patients with Myelodysplastic Syndromes (MDS)
Eytan M. Stein, USA

Oral Abstract Presentation:

Updated results from Phase 2 Study of Guadecitabine for Patients with Untreated Int-2/High Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Guillermo Montalban-Bravo, USA

13:30 – 15:00

13:45-14:45
Industry Supported session not included in the CME/CPD Program

Lunch Break, Exhibition & Poster Viewing

	<p>Therapy-3 Allogeneic Hematopoietic Cell Transplantation</p> <p>Chairs: Theo de Witte, The Netherlands (TBA) Jaime Sanz, Spain</p> <p>Candidates and timing Theo de Witte, The Netherlands</p> <p>Pre- and post-transplant strategies to reduce relapse Charles Craddock, UK</p> <p>New stem cell donor sources and regimens for transplantation David Valcarcel, Spain</p> <p><i>Oral Abstract Presentation:</i> Allogeneic hematopoietic stem cell transplantation for patients aged 60 years or older with myelodysplastic syndrome in Japan Hidehiro Itonaga, Japan</p> <p><i>Oral Abstract Presentation:</i> Chronic GVHD Could Ameliorate the Impact of Adverse Somatic Mutations in Patients with Myelodysplastic Syndromes and Hematopoietic Stem Cell Transplantation Juan Carlos Caballero, Spain</p>		<p>Pharmacist Session A What a Pharmacist Should Know About MDS?</p> <p>Chairs: Albert Asunción, Spain</p> <p>Diagnosis and evaluation of response Guillermo Sanz, Spain</p> <p>Treatment of higher-risk MDS patients Hannah Kershaw, UK</p> <p>Treatment of lower-risk MDS patients Garbiñe Lizeaga, Spain</p>	<p>Patient Forum 15:00-18:15</p> <p>Chairs: Andrés Jerez, Spain Begoña Barragán, Spain</p> <p>Patient Arrival and Registration Registro de asistentes</p> <p>Welcome and presentation Bienvenida – Introducción a la jornada Andrés Jerez, Spain</p> <p>The MDS Foundation’s Building Blocks of Hope: Quick Tips for Patients and Caregivers</p> <p>Consejos breves para pacientes y cuidadores: Programa “Dando paso a la esperanza” de la MDS Foundation. Andrés Jerez, Spain</p> <p>Emotional and social impact of myelodysplastic syndromes: recommendations for patients and relatives Impacto emocional y social de los Síndromes Mielodisplásicos: recomendaciones para pacientes y familiares Miguel Rojas Cásares, Spain</p>
<p>15:00-16:30</p>	<p>Coffee Break, Exhibition & Poster Viewing</p>			
<p>16:30-17:00</p>				

<p>17:00 – 18:15</p>	<p>Caring for Patient with MDS</p> <p>Chairs: Santiago Bonanad, Spain Reinhard Stauder, Austria</p> <p>Iron overload in MDS. Is there something new? Norbert Gattermann, Germany</p> <p>Thrombocytopenia in MDS Valeria Santini, Italy</p> <p>Comorbidity index and comprehensive geriatric assessment in treatment decision Fernando Ramos, Spain</p>	<p>Controversial Issues in MDS</p> <p>Chairs: Lourdes Florensa, Spain Torsten Haferlach, Germany</p> <p>How do I diagnose MDS using currently available tools? Torsten Haferlach, Germany</p> <p>Choosing the appropriate denominator for counting BM blasts Leonor Arenillas, Spain</p> <p>Do all MDS subtypes reduce life expectancy? Arturo Pereira, Spain</p>	<p>Pharmacist Session B Hematologic Geriatric Patients</p> <p>Chairs: Amparo Burgos, Spain</p> <p>Geriatric assessment and multidisciplinary teams. Raúl Córdoba, Spain</p> <p>Pharmacists role in hematologic geriatric patients Estela Moreno, Spain</p>	<p>New Therapies and Patient Treatment Options Nuevas opciones y estrategias de tratamiento en SMD Guillermo García-Manero, USA</p> <p>Round-table Q&A</p> <p>Mesa Redonda y foro debate con asistentes. Guillermo García-Manero, USA Miguel Rojas Cásares, Spain Andrés Jerez, Spain</p>
<p>18:00-19:15</p>	<p>Guided Poster Session</p> <p>Clinical Cases (6 posters selected for discussion)</p> <p>Chairs: Teresa Vallespí, Spain Wolf. K. Hofmann, Germany</p> <p>Biological & Research Studies (6 posters selected for discussion)</p> <p>Chairs: Jaroslaw Maciejewski, USA Elli Papaemmanuil, USA</p> <p>Clinical Studies (6 posters selected for discussion)</p> <p>Chairs: Eva Hellström-Lindberg, Sweden Moshe Mittelman, Israel</p>			
<p>19:15</p>	<p>Networking Event</p>			

Saturday May 6, 2017

Time	Auditorium 1	Auditorium 2	Auditorium 3
08:30 - 10:00	<p style="text-align: center;">Oral Session 3</p> <p style="text-align: center;">Chairs: Michael Savona, USA David Valcarcel, Spain</p> <p style="text-align: center;">A Phase 3 Randomized Placebo (Pbo)-Controlled Double-Blind Trial of Darbepoetin Alfa in Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndromes (MDS) Uwe Platzbecker, Germany</p> <p style="text-align: center;">Combination of Oral Rigosertib And Injectable Azacitidine In Patients with Myelodysplastic Syndromes (MDS) Shyamala Navada, USA</p> <p style="text-align: center;">A Retrospective Validation of International Consortium for MDS/MPN Response Criteria in CMML Treated with Hypomethylating Agents Matthieu Duchmann, France</p> <p style="text-align: center;">Luspatercept Response in New Subpopulations of Patients with Lower-Risk Myelodysplastic Syndromes (MDS): Update of the PACE Study Uwe Platzbecker, USA</p> <p style="text-align: center;">Robust Patient-Derived Xenografts (PDX) Capture the Disease Fidelity of Chronic Myelomonocytic Leukemia (CMML) and Juvenile Myelomonocytic Leukemia (JMML) Eric Padron, USA</p> <p style="text-align: center;">Phase 2 study of selinexor in patients with myelodysplastic syndromes refractory to hypomethylating agents: Interim report Virginia M. Klimek, USA</p>	<p style="text-align: center;">Oral Session 4</p> <p style="text-align: center;">Chairs: Francesc Solé, Spain Peter L. Greenberg, USA</p> <p style="text-align: center;">Chromosomal aberrations in therapy-related myelodysplastic syndromes - relations to primary disease, therapy and prognostic significance Meritxell Nomdedeu, Spain</p> <p style="text-align: center;">Outcome of Lower-Risk Patients with Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis Stimulating Agents- Sophie Park, France</p> <p style="text-align: center;">Adding Molecular Data to Prognostic Models can improve its Predictive Power in Treated Patients with Myelodysplastic Syndromes (MDS) Aziz Nazha, USA</p> <p style="text-align: center;">A single Next-Generation Sequencing (NGS) assay for the detection of point mutations and large chromosomal abnormalities in MDS patients Alessandro Liquori, Spain</p> <p style="text-align: center;">Identification of The Specific Hematopoietic Stem Cell Populations Responsible for Failure to Hypomethylating Agents in Myelodysplastic Syndromes Irene Ganán-Gomez, USA</p> <p style="text-align: center;">Autophagy Stimulation Improves Erythroid Proliferative Capacity in Models of SF3B1 Mutant MDS Valeria Visconte, USA</p>	
10:00 - 10:30	Coffee Break		

10:30 - 12:00

Tito Bastianello and MDS Foundation Young Investigators Award

Chairs:
Guillermo Sanz
Stephen D. Nimer

HIF1A signaling is a central pathobiologic mediator of MDS
Yoshihiro Hayashi, USA

An Analysis of The Transcriptional Response of Myelodysplastic Syndrome Stem Cells to Therapy at SingleCell Resolution
Stephen Chung, USA

Mutational signature and clonal architecture of low risk Myelodysplastic Syndromes with del(5q)
Vera Adema, USA

Labile Plasma Iron predicts for survival in patients undergoing allogeneic stem cell-transplantation – results from the prospective multicenter German-Austrian ALLIVE trial
Martin Wermke, Germany

MDS Foundation Young Investigators Award Announcement

David Sallman, USA
Yoshihiro Hayashi, USA

Closing Remarks and Farewell

Chairs:

Guillermo Sanz, Spain
Stephen D. Nimer, USA

Announcement of the 15th International Symposium on
MDS, Copenhagen, 2019

Lars Kjeldsen, Denmark
Kirsten Grønbaek, Denmark

Closing Remarks & Farewell

Guillermo Sanz, Spain
Stephen D. Nimer, USA

12:00 - 12:30